Elanco Animal Health (NYSE:ELAN) Now Covered by Leerink Partners

Leerink Partners started coverage on shares of Elanco Animal Health (NYSE:ELAN) in a report published on Monday, MarketBeat reports. The firm issued a market perform rating and a $14.00 target price on the stock.

A number of other equities analysts also recently commented on ELAN. Stifel Nicolaus restated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a research report on Thursday, September 19th. Barclays upped their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Finally, Morgan Stanley cut shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $17.00 to $15.00 in a research note on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $16.75.

Elanco Animal Health Stock Down 1.8 %

ELAN stock opened at $12.25 on Monday. The company has a fifty day moving average price of $13.52 and a 200 day moving average price of $14.55. Elanco Animal Health has a 12 month low of $11.40 and a 12 month high of $18.80. The company has a market cap of $6.06 billion, a price-to-earnings ratio of 30.63, a price-to-earnings-growth ratio of 1.41 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s quarterly revenue was down 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.18 EPS. Sell-side analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Large investors have recently added to or reduced their stakes in the business. Tidal Investments LLC lifted its holdings in Elanco Animal Health by 34.6% in the 1st quarter. Tidal Investments LLC now owns 22,575 shares of the company’s stock valued at $368,000 after purchasing an additional 5,797 shares in the last quarter. Comerica Bank raised its holdings in Elanco Animal Health by 272.6% in the first quarter. Comerica Bank now owns 11,716 shares of the company’s stock valued at $191,000 after buying an additional 8,572 shares during the period. Cetera Advisors LLC acquired a new stake in Elanco Animal Health in the first quarter valued at approximately $213,000. Clarus Wealth Advisors acquired a new stake in Elanco Animal Health in the second quarter valued at approximately $449,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Elanco Animal Health during the second quarter worth approximately $401,000. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.